Focal brain inflammation and autism

Theoharis C Theoharides

Shahrzad Asadi

Arti B Patel

Abstract

Introduction

Focal brain inflammation

Increasing evidence indicates that brain inflammation is important in the pathogenesis of neuropsychiatric disorders [1,2]. Autism spectrum disorders (ASD) are pervasive neuro-developmental disorders characterized by varying degrees of deficiencies in social interactions, intelligence, and language, as well as the presence of stereotypic behaviors [3-6]. Recent results from the Centers of Disease Control in the USA indicate that as many as 1/80 children have ASD [7]. Many such children regress at about age 3 years, often after a specific event such as reaction to vaccination, infection [8,9], trauma [10,11], toxic exposures [12] or stress [13], implying the importance of some environmental triggers [14,15].

Increasing evidence points to some immune dysfunction/inflammation in ASD [16,17]. The markers of inflammation identified in the brain and cerebrospinal fluid (CSF) of many ASD patients include TNF, IL-6 and monocyte chemotactic protein 1 (MCP-1), the latter of which also is chemotactic for mast cells [18]. Pro-inflammatory cytokine mRNA (IL-1α, IL-1β, IL-6 and TNF-α) is increased in brain inflammation and has been associated with hippocampal and cerebral damage [8]. Mast cells are a rich source of IL-6 and TNF [19]. In fact, mast cells are the only immune cells that store pre-formed TNF and can release it rapidly upon stimulation [20].

Mast cells and cytokines such as IL-6 and TNF are also implicated in disruption of the blood–brain barrier (BBB) [21-23], which may be malfunctioning or leaky in ASD as evidenced by the presence of circulating auto-antibodies directed against the fetal brain proteins [24-27]. We had reported that the cytokine IL-33 synergizes with inflammatory neuropeptides to stimulate mast cells and result in increased vascular permeability [28]. IL-33 has been considered an alarmin, acting through mast cells to alert the innate immune system [29,30], and has recently been linked to brain inflammation [31-33].

We have also reported that neurotensin (NT) and corticotropin-releasing hormone (CRH), secreted under stress, synergistically stimulate mast cells, leading to increase vascular permeability [34] and contribute to BBB disruption [35]. We further showed that NT stimulates mast cell secretion of vascular endothelial growth factor (VEGF) [36], which is also vasodilatory. NT also increases expression of CRH receptor-1 (CRHR-1) [37], activation of which by CRH increases allergic stimulation of human mast cells [38].

NT is a vasoactive peptide originally isolated from the brain [39], but also found in the gut where it has been implicated in inflammation [40], and in increased intestinal permeability in rodents [41]. NT is also increased in the skin following acute stress, stimulates skin mast cells and increases vascular permeability in rodents [42]. NT stimulates rodent peritoneal mast cells to secrete histamine and elevates histamine plasma levels through activation of specific NT receptors (NTR) [43-45]. Moreover, NT is rapidly degraded by mast cell proteases [34,46] implying tight regulation of its activity.

Mast cells are hemopoietic-derived tissue immune cells responsible for allergies, but also implicated in immunity [47] and inflammation [18]. Mast cells can produce both pro- and anti-inflammatory mediators [48] and may have immuno-modulatory functions [47,49-51]. It is, therefore, of interest that allergic-like reactions are common in ASD children [52,53] implying activation of mast cells by non-allergic triggers [17]. The richest source of mast cells in the brain is the diencephalon [54] that regulates behavior, while the highest concentration of NTR is in the Broca area [55], which regulates language, known to be lost in many children with ASD. Mast cells are responsible for eliciting neutrophil infiltration that promotes inflammation [56]. Mast cell-microglial interactions are important in neuroinflammatory diseases [57,58]. Microglia are the innate brain immune cells that are increasingly implicated in a number of neuropsychiatric diseases [59]. In fact, abnormal microglial growth and activation was recently reported in the brain of ASD patients [60,61]. Microglia express NTR3, activation of which leads to their proliferation [62].

NT has additional actions that are relevant to ASD (Table 1): it induces intestinal secretion and mobility [63], stimulates glial cell proliferation [64], and can facilitate seizures through activation of glutamate receptors [65]. In fact, the glutamate receptor mGluR5 was reported to be overactive in fragile X mice [66,67], a condition associated with high risk of ASD. In other words, NT could contribute to ASD pathogenesis through different mechanisms (Figure 1).

Table 1

Neurotensin actions relevant to autism spectrum disorder (ASD) pathogenesis

Effect	Result
Activation and proliferation of microglia	Brain inflammation
Activation of mast cells	Blood–brain-barrier disruption and inflammation
Disruption of gut-blood barrier	Leaky gut and inflammation
Mast cell stimulation, especially in the subgroup of ASD patients with allergic symptoms	Augmentation of allergic symptoms
Extracellular secretion of mitochondrial components that act as innate pathogens	Inflammation
Stimulation of glutamate receptors	Neuronal damage
Direct neurotoxicity	Neuronal damage

Figure 1

Diagrammatic representation of how stimulation of mast cells and microglia could lead to multiple effects that contribute brain inflammation and the pathogenesis and symptoms of autism. MCP, monocyte chemotactic protein.

There is also support for increased oxidative stress [68] and some mitochondrial (mt) defects at least in subgroups of patients with ASD [69]. We showed that mtDNA is significantly increased in the serum of young autistic children [70], who also had significantly increased serum level of NT [71]; this triggers mast cells to secrete mtDNA [38] that acts as innate pathogen to stimulate mast cells [72] and other immune cells, leading to auto-inflammation [73]. Moreover, mtDNA can cause neuronal degeneration and altered behavior [74]. We believe that ASD originate from immune perinatal insults [75,76] that activate ASD susceptibility genes leading to focal encephalitis (Table 2).

Table 2

Key pathologic processes in ASD^*

Change	Pathologic processes
↑	Allergic-like symptoms
↑	Anti-brain protein auto-antibodies
↑	Food intolerance
↑	Brain and gut inflammatory markers
↑	High anxiety and response to stress
↑	Oxidative stress
↓	Glutathione
↓	Methylation, sulfation

^*Not present all ASD children.

Epigenetic activation of ASD susceptibility genes

In spite of the fact that almost 100 gene mutations have been identified in patients with ASD [77,78], they do not explain more than a few percent of ASD cases [6]. High risk for developing ASD has been associated with mutations leading to decreased phosphatase and tensin homolog (PTEN) and tuberous sclerosis protein 1 and 2 (TSC1/2) [77]. These proteins are upstream inhibitors of the mammalian target of rapamycin (mTOR) [77,79], which leads to microglia and mast cell proliferation [80,81]. Activation of susceptibility genes is being increasingly invoked to explain ASD [7,82]. A recent paper reported that offspring of maternal immune activation in mice led to increased IL-6 and IL-17, and contributed to ASD-related behaviors [9]; repopulation of control irradiated mice with bone marrow derived from affected mothers did not induce those effects suggesting the contribution of some epigenetic environmental influences. Stimulation of mTOR in subjects with overactive mTOR due to gene mutations, leading to low PTEN, would contribute to a form of epigenetic signal.

Novel treatments

Behavioral interventions are the most common treatment approaches [83], but do not address the core ASD symptoms [84,85]. Psychotropic drugs are used much too often in ASD [86-88]. Such drugs include antipsychotic medications [89], the newer atypical compounds [90,91] risperidone [92,93] and aripiprazole [94] for obsessive-compulsive symptoms, aggression and self-injury, as well as methylphenidate for hyperactivity [95]. However, two recent reviews concluded that there is insufficient evidence to support any benefit of psychotropic drugs [96] or selective serotonin re-uptake inhibitor (SSRIs) [97] in ASD. In fact, the SSRI citalopram may actually be detrimental [98], especially in children [99]. Moreover, a recent paper reported that citalopram administration perinataly altered cortical network function and led to ASD-like behaviors in rodents [100].

Rapamycin and its analogs are mTOR inhibitors [101] and are being tried for treatment of ASD [102-105] (Figure 2). Our preliminary results (not shown) indicate for the first time that the natural flavonoid luteolin [106] is more potent that rapamycin in its ability to inhibit human mast cell TNF release (Figure 2). A previous report also indicated that flavonoid-related epigallocatechin gallate (EGCG) is an mTOR inhibitor [107]. Luteolin may not only inhibit mTOR, but also has additional beneficial effects in brain inflammation. It inhibits oxidative stress [106], inflammation [106], mast cell degranulation [108], mast cell cytokine release [38], thimerosal-induced inflammatory mediator release [109], microglial activation and proliferation [110-112], and auto-immune T cell activation [113,114]. Luteolin is also protective against methylmercury-induced mitochondrial damage [115], is neuroprotective [116] and mimics brain-derived neurotrophic factor (BDNF) [117], which was recently associated with autistic-like-behavior in mice [118]. Finally, luteolin could reverse ASD-like behavior in mice [53], and was recently shown to have significant benefit in children with ASD [38,119].

Figure 2

Diagrammatic representation of the mTOR pathway, how it may lead to increased risk of autism and the inhibitory effect of luteolin. mTOR, mammalian target of rapamycin; PTEN, phosphatase and tensin homolog; AKT, protein kinase B.

Conclusions

The prevalence of ASD continues to rise, but there is no clinically effective drug for the core ASD symptoms. Unfortunately, the lack of distinct pathogenesis and biomarkers makes it difficult to develop effective treatments. Stimulation of mTOR, which is already activated due to PTEN mutations, by NT, CRH and/or IL-33, could serve as novel targets for drug development. NTR and CRHR-1 antagonists could, therefore, be used in ASD, along with luteolin.

Abbreviations

ASD: autism spectrum disorders; BBB: blood–brain barrier; BDNF: brain-derived neurotrophic factor; CSF: cerebrospinal fluid; CRH: corticotropin-releasing hormone; EGCG: epigallocatechin gallate; IL: interleukin; MCP: monocyte chemotactic protein; mTOR: mammalian target of rapamycin; mt: mitochondrial; NT: neurotensin; NTR: neurotensin receptor; PTEN: phosphatase and tensin homolog; SSRI: selective serotonin re-uptake inhibitor; TNF: tumor necrosis factor; TSC1/2: tuberous sclerosis protein 1 and 2; VEGF: vascular endothelial growth factor.

Competing interests

The authors declare they have no competing interests.

Authors’ contributions

TCT, SA, and AP conceived and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Aspects of the work discussed were funded in part by the Autism Research Institute, the National Autism Association, Safe Minds, and Theta Biomedical Consulting and Development Co. Inc. (Brookline, MA).

References

1. TheoharidesTCZhangBContiPDecreased mitochondrial function and increased brain inflammation in bipolar disorder and other neuropsychiatric diseasesJ Clin Psychopharmacol201131685687[PubMed][Google Scholar]
2. HagbergHGressensPMallardCInflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adultsAnn Neurol201271444457[PubMed][Google Scholar]
3. FombonneEEpidemiology of pervasive developmental disordersPediatr Res200965591598[PubMed][Google Scholar]
4. JohnsonCPMyersSMIdentification and evaluation of children with autism spectrum disordersPediatrics200712011831215[PubMed][Google Scholar]
5. McPartlandJVolkmarFRAutism and related disordersHandb Clin Neurol2012106407418[PubMed][Google Scholar]
6. AbrahamsBSGeschwindDHAdvances in autism genetics: on the threshold of a new neurobiologyNat Rev Genet20089341355[PubMed][Google Scholar]
7. WilliamsSCGenetics: searching for answersNature2012491S4S6[PubMed][Google Scholar]
8. HornigMWeissenbockHHorscroftNLipkinWIAn infection-based model of neurodevelopmental damageProc Natl Acad Sci USA1999961210212107[PubMed][Google Scholar]
9. HsiaoEYMcBrideSWChowJMazmanianSKPattersonPHModeling an autism risk factor in mice leads to permanent immune dysregulationProc Natl Acad Sci USA20121091277612781[PubMed][Google Scholar]
10. BlennerSReddyAAugustynMDiagnosis and management of autism in childhoodBMJ2011343d6238[PubMed][Google Scholar]
11. RapinITuchmanRFWhat is new in autism?Curr Opin Neurol200821143149[PubMed][Google Scholar]
12. DethRMuratoreCBenzecryJPower-CharnitskyVAWalyMHow environmental and genetic factors combine to cause autism: a redox/methylation hypothesisNeurotoxicology200829190201[PubMed][Google Scholar]
13. LanniKESchuppCWSimonDCorbettBAVerbal ability, social stress, and anxiety in children with autistic disorderAutism201216123138[PubMed][Google Scholar]
14. HerbertMRContributions of the environment and environmentally vulnerable physiology to autism spectrum disordersCurr Opin Neurol201023103110[PubMed][Google Scholar]
15. GoinesPEAshwoodPCytokine dysregulation in autism spectrum disorders (ASD): Possible role of the environmentNeurotoxicol Teratol2012[PubMed][Google Scholar]
16. OnoreCCareagaMAshwoodPThe role of immune dysfunction in the pathophysiology of autismBrain Behav Immun201226383392[PubMed][Google Scholar]
17. TheoharidesTCAngelidouAAlysandratosKDZhangBAsadiSFrancisKToniatoEKalogeromitrosDMast cell activation and autismBiochim Biophys Acta182220123441[Google Scholar]
18. TheoharidesTCAlysandratosKDAngelidouADelivanisDASismanopoulosNZhangBAsadiSVasiadiMWengZMiniatiAKalogeromitrosDMast cells and inflammationBiochim Biophys Acta182220102133[Google Scholar]
19. NorrbyKMast cells and de novo angiogenesis: angiogenic capability of individual mast-cell mediators such as histamine, TNF, IL-8 and bFGFInflamm Res199746Suppl. 1S7S8[PubMed][Google Scholar]
20. ZhangBWengZSismanopoulosNAsadiSTherianouAAlysandratosKDAngelidouAShirihaiOTheoharidesTCMitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cellsInt Arch Allergy Immunol201215912332[PubMed][Google Scholar]
21. GalliSJNew concepts about the mast cellN Engl J Med1993328257265[PubMed][Google Scholar]
22. TheoharidesTCDoyleRAutism, gut-blood–brain barrier and mast cellsJ Clin Psychopharm200828479483[PubMed][Google Scholar]
23. KimKSWassCACrossASOpalSMModulation of blood–brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the ratLymphokine Cytokine Res199211293298[PubMed][Google Scholar]
24. RossiCCVan de WaterJRogersSJAmaralDGDetection of plasma autoantibodies to brain tissue in young children with and without autism spectrum disordersBrain Behav Immun20112511231135[PubMed][Google Scholar]
25. BraunschweigDAshwoodPKrakowiakPHertz-PicciottoIHansenRCroenLAPessahINVan de WaterJAutism: maternally derived antibodies specific for fetal brain proteinsNeurotoxicology200829226231[PubMed][Google Scholar]
26. BraunschweigDDuncansonPBoyceRHansenRAshwoodPPessahINHertz-PicciottoIVan de WaterJBehavioral correlates of maternal antibody status among children with autismJ Autism Dev Disord201242714351445[PubMed][Google Scholar]
27. BraunschweigDVan de WaterJMaternal autoantibodies in autismArch Neurol201269693699[PubMed][Google Scholar]
28. TheoharidesTCZhangBKempurajDTagenMVasiadiMAngelidouAAlysandratosKDKalogeromitrosDAsadiSStavrianeasNPetersonELeemanSContiPIL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skinProc Natl Acad Sci USA201010744484453[PubMed][Google Scholar]
29. MoussionCOrtegaNGirardJPThe IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?PLoS One20083e3331[PubMed][Google Scholar]
30. EnokssonMLybergKMoller-WesterbergCFallonPGNilssonGLunderius-AnderssonCMast cells as sensors of cell injury through IL-33 recognitionJ Immunol201118625232528[PubMed][Google Scholar]
31. ZhaoYYWeirMAMannoMCordyPGomesTHackamDGJuurlinkDNMamdaniMMoistLParikhCRPatersonJMWaldRYaoZGargAXNew fibrate use and acute renal outcomes in elderly adults: a population-based studyAnn Intern Med2012156560569[PubMed][Google Scholar]
32. PicheryMMireyEMercierPLefrancaisEDujardinAOrtegaNGirardJPEndogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strainJ Immunol201218834883495[PubMed][Google Scholar]
33. ChakrabortySKaushikDKGuptaMBasuAInflammasome signaling at the heart of central nervous system pathologyJ Neurosci Res20108816151631[PubMed][Google Scholar]
34. DonelanJBoucherWPapadopoulouNLytinasMPapaliodisDTheoharidesTCCorticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent processProc Natl Acad Sci USA200610377597764[PubMed][Google Scholar]
35. TheoharidesTCKonstantinidouACorticotropin-releasing hormone and the blood–brain-barrierFront Biosci20071216151628[PubMed][Google Scholar]
36. VasiadiMTherianouAAlysandratosKDKatsarou-KatsariAPetrakopoulouTTheoharidesAPapadavidEStavrianeasNAntoniouCKalogeromitrosDTheoharidesTCSerum neurotensin (NT) is increased in psoriasis and NT induces VEGF release from human mast cellsBr J Dermatol201216613491352[PubMed][Google Scholar]
37. AlysandratosK-DAsadiSAngelidouAZhangBSismanopoulosNYangHCritchfieldATheoharidesTCNeurotensin and CRH interactions augment human mast cell activationPLoS ONE2012711e48934[PubMed][Google Scholar]
38. AsadiSTheoharidesTCCorticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolinJ Neuroinflam2012985[PubMed][Google Scholar]
39. CarrawayRLeemanSEThe isolation of a new hypotensive peptide, neurotensin, from bovine hypothalamiJ Biol Chem197324868546861[PubMed][Google Scholar]
40. Tyler-McMahonBMBoulesMRichelsonENeurotensin: peptide for the next millenniumRegul Pept200093125136[PubMed][Google Scholar]
41. CarrawayRESingerEAFerrisCFMitraSPGeneration of immunoreactive neurotensin(s) and enkephalin(s) by pepsin-treatment of plasmaAdv Exp Med Biol1986198 Pt B169179[PubMed][Google Scholar]
42. SinghLKPangXAlexacosNLetourneauRTheoharidesTCAcute immobilization stress triggers skin mast cell degranulation via corticotropin-releasing hormone, neurotensin and substance P: a link to neurogenic skin disordersBrain Behav Immunity199913225239[PubMed][Google Scholar]
43. CarrawayRCochraneDELansmanJBLeemanSEPatersonBMWelchHJNeurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levelsJ Physiol1982323403414[PubMed][Google Scholar]
44. FeldbergRSCochraneDECarrawayREBrownEBSawyerRHartunianMWentworthDEvidence for a neurotensin receptor in rat serosal mast cellsInflamm Res199847245250[PubMed][Google Scholar]
45. BarrocasAMCochraneDECarrawayREFeldbergRSNeurotensin stimulation of mast cell secretion is receptor-mediated, pertussis-toxin sensitive and requires activation of phospholipase CImmunopharmacology199941131137[PubMed][Google Scholar]
46. CochraneDECarrawayREBoucherWFeldbergRSRapid degradation of neutotensin by stimulated rat mast cellsPeptides19911211871194[PubMed][Google Scholar]
47. KalesnikoffJGalliSJNew developments in mast cell biologyNat Immunol2008912151223[PubMed][Google Scholar]
48. KobayashiHIshizukaTOkayamaYHuman mast cells and basophils as sources of cytokinesClin Exp Allergy20003012051212[PubMed][Google Scholar]
49. GalliSJGrimbaldestonMTsaiMImmunomodulatory mast cells: negative, as well as positive, regulators of immunityNat Rev Immunol20088478486[PubMed][Google Scholar]
50. KawakamiTA crucial door to the mast cell mystery knocked inJ Immunol200918368616862[PubMed][Google Scholar]
51. PiconeseSCostanzaMMusioSTripodoCPolianiPLGriGBurocchiAPittoniPGorzanelliAColomboMPPedottiRExacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient Kit W-sh/W-sh miceLab Invest201191627641[PubMed][Google Scholar]
52. KoganMDBlumbergSJSchieveLABoyleCAPerrinJMGhandourRMSinghGKStricklandBBTrevathanEvan DyckPCPrevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007Pediatrics2009513951403[PubMed][Google Scholar]
53. AngelidouAAlysandratosKDAsadiSZhangBFrancisKVasiadiMKalogeromitrosDTheoharidesTCBrief report: “allergic symptoms” in children with autism spectrum disorders. More than meets the eye?J Autism Dev Disord20114115791585[PubMed][Google Scholar]
54. PangXLetourneauRRoznieckiJJWangLTheoharidesTCDefinitive characterization of rat hypothalamic mast cellsNeuroscience199673889902[PubMed][Google Scholar]
55. FassioAEvansGGrisshammerRBolamJPMimmackMEmsonPCDistribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibodyNeuropharmacology20003914301442[PubMed][Google Scholar]
56. WalkerMEHatfieldJKBrownMANew insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action?Biochim Biophys Acta182220125765[Google Scholar]
57. SkaperSDGiustiPFacciLMicroglia and mast cells: two tracks on the road to neuroinflammationFASEB J20122631033117[PubMed][Google Scholar]
58. SkaperSDFacciLMast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamidePhilos Trans R Soc Lond B Biol Sci201236733123325[PubMed][Google Scholar]
59. NagaiANakagawaEHatoriKChoiHBMcLarnonJGLeeMAKimSUGeneration and characterization of immortalized human microglial cell lines: expression of cytokines and chemokinesNeurobiol Dis2001810571068[PubMed][Google Scholar]
60. MorganJTChanaGAbramsonISemendeferiKCourchesneEEverallIPAbnormal microglial-neuronal spatial organization in the dorsolateral prefrontal cortex in autismBrain Res201214567281[PubMed][Google Scholar]
61. RodriguezJIKernJKEvidence of microglial activation in autism and its possible role in brain underconnectivityNeuron Glia Biol20117205213[PubMed][Google Scholar]
62. MartinSDicouEVincentJPMazellaJNeurotensin and the neurotensin receptor-3 in microglial cellsJ Neurosci Res200581322326[PubMed][Google Scholar]
63. RieglerMCastagliuoloIWangCWlkMSogukogluTWenzlEMatthewsJBPothoulakisCNeurotensin stimulates Cl(−) secretion in human colonic mucosa In vitro: role of adenosineGastroenterology2000119348357[PubMed][Google Scholar]
64. MartinSVincentJPMazellaJInvolvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microgliaJ Neurosci20032311981205[PubMed][Google Scholar]
65. GhanizadehATargeting neurotensin as a potential novel approach for the treatment of autismJ Neuroinflammation2010758[PubMed][Google Scholar]
66. BearMFDolenGOsterweilENagarajanNFragile X: translation in actionNeuropsychopharmacology2008338487[PubMed][Google Scholar]
67. MichalonASidorovMBallardTMOzmenLSpoorenWWettsteinJGJaeschkeGBearMFLindemannLChronic pharmacological mGlu5 inhibition corrects fragile X in adult miceNeuron2012744956[PubMed][Google Scholar]
68. RossignolDAFryeREA review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposuresMol Psychiatry2012174389401[PubMed][Google Scholar]
69. RossignolDAFryeREMitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysisMol. Psychiatry201217290314[PubMed][Google Scholar]
70. ZhangBAngelidouAAlysandratosKDVasiadiMFrancisKAsadiSTheoharidesASideriKLykourasLKalogeromitrosDTheoharidesTCMitochondrial DNA and anti-mitochondrial antibodies in serum of autistic childrenJ Neuroinflammation2010780[PubMed][Google Scholar]
71. AngelidouAFrancisKVasiadiMAlysandratosK-DZhangBTheoharidesALykourasLKalogeromitrosDTheoharidesTCNeurotensin is increased in serum of young children with autistic disorderJ Neuroinflam2010748[PubMed][Google Scholar]
72. ZhangBAlysandratosKDAngelidouAAsadiSSismanopoulosNDelivanisDAWengZMiniatiAVasiadiMKatsarou-KatsariAMiaoBLeemanSEKalogeromitrosDTheoharidesTCHuman mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitisJ Allergy Clin Immunol201112715221531[PubMed][Google Scholar]
73. ZhangBAsadiSWengZSismanopoulosNTheoharidesTCStimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actionsPLoS ONE2012712e49767[PubMed][Google Scholar]
74. LauritzenKHMoldestadOEideLCarlsenHNesseGStormJFMansuyIMBergersenLHKlunglandAMitochondrial DNA toxicity in forebrain neurons causes apoptosis, neurodegeneration, and impaired behaviorMol Cell Biol20103013571367[PubMed][Google Scholar]
75. AngelidouAAsadiSAlysandratosKDKaragkouniAKourembanasSTheoharidesTCPerinatal stress, brain inflammation and risk of autism-Review and proposalBMC Pediatr20121289[PubMed][Google Scholar]
76. TheoharidesTCKempurajDRedwoodLAutism: an emerging ‘neuroimmune disorder’ in search of therapyExp Opin Pharmacother20091021272143[PubMed][Google Scholar]
77. AldingerKAPlummerJTQiuSLevittPSnapShot: genetics of autismNeuron201172418[PubMed][Google Scholar]
78. BetancurCEtiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still countingBrain Res201113804277[PubMed][Google Scholar]
79. ZhouJParadaLFPTEN signaling in autism spectrum disordersCurr Opin Neurobiol2012225873879[PubMed][Google Scholar]
80. SmrzDKimMSZhangSMockBASmrzovaSDuBoisWSimakovaOMaricIWilsonTMMetcalfeDDGilfillanAMmTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cellsBlood201111868036813[PubMed][Google Scholar]
81. ShangYCChongZZWangSMaieseKErythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microgliaCurr Neurovasc Res20118270285[PubMed][Google Scholar]
82. WeissLAArkingDEDalyMJChakravartiAA genome-wide linkage and association scan reveals novel loci for autismNature2009461802808[PubMed][Google Scholar]
83. GerhardTChavezBOlfsonMCrystalSNational patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorderJ Clin Psychopharmacol200929307310[PubMed][Google Scholar]
84. LangRMahoneyREl ZeinFDelauneEAmidonMEvidence to practice: treatment of anxiety in individuals with autism spectrum disordersNeuropsychiatr Dis Treat201172730[PubMed][Google Scholar]
85. WarrenZMcPheetersMLSatheNFoss-FeigJHGlasserAVeenstra-VanderweeleJA systematic review of early intensive intervention for autism spectrum disordersPediatrics2011127e1303e1311[PubMed][Google Scholar]
86. MunshiKRGonzalez-HeydrichJAugensteinTD’AngeloEJEvidence-based treatment approach to autism spectrum disordersPediatr Ann201140569574[PubMed][Google Scholar]
87. NazeerAPsychopharmacology of autistic spectrum disorders in children and adolescentsPediatr Clin North Am2011588597[PubMed][Google Scholar]
88. ParikhMSKolevzonAHollanderEPsychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerabilityJ Child Adolesc Psychopharmacol200818157178[PubMed][Google Scholar]
89. PoseyDJStiglerKAEricksonCAMcDougleCJAntipsychotics in the treatment of autismJ Clin Invest2008118614[PubMed][Google Scholar]
90. ChavezBChavez-BrownMSopkoMAJrReyJAAtypical antipsychotics in children with pervasive developmental disordersPaediatr Drugs20079249266[PubMed][Google Scholar]
91. McDougleCJStiglerKAEricksonCAPoseyDJAtypical antipsychotics in children and adolescents with autistic and other pervasive developmental disordersJ Clin Psychiatry200869Suppl 41520[PubMed][Google Scholar]
92. McCrackenJTMcGoughJShahBCroninPHongDAmanMGArnoldLELindsayRNashPHollwayJMcDougleCJPoseyDSwiezyNKohnAScahillLMartinAKoenigKVolkmarFCarrollDLancorATierneyEGhumanJGonzalezNMGradosMVitielloBRitzLDaviesMRobinsonJMcMahonDRisperidone in children with autism and serious behavioral problemsN Engl J Med2002347314321[PubMed][Google Scholar]
93. ScottLJDhillonSRisperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescentsPaediatr Drugs20079343354[PubMed][Google Scholar]
94. CurranMPAripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patientsPaediatr Drugs201113197204[PubMed][Google Scholar]
95. Research Units on Pediatric Psychparmacology Autism NetworkRandomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivityArch Gen Psychiatry20056212661274[PubMed][Google Scholar]
96. McPheetersMLWarrenZSatheNBruzekJLKrishnaswamiSJeromeRNVeenstra-VanderweeleJA systematic review of medical treatments for children with autism spectrum disordersPediatrics2011127e1312e1321[PubMed][Google Scholar]
97. WilliamsKWheelerDMSiloveNHazellPSelective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)Cochrane Database Syst Rev20108CD004677[PubMed][Google Scholar]
98. KingBHHollanderESikichLMcCrackenJTScahillLBregmanJDDonnellyCLAnagnostouEDukesKSullivanLHirtzDWagnerARitzLLack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autismArch Gen Psychiatry200966583590[PubMed][Google Scholar]
99. VolkmarFRCitalopram treatment in children with autism spectrum disorders and high levels of repetitive behaviorArch Gen Psychiatry200966581582[PubMed][Google Scholar]
100. CorrellCUKratochvilCJMarchJSDevelopments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychoticsJ Clin Psychiatry201172655670[PubMed][Google Scholar]
101. ZhouHLuoYHuangSUpdates of mTOR inhibitorsAnticancer Agents Med Chem201010571581[PubMed][Google Scholar]
102. EhningerDSilvaAJRapamycin for treating Tuberous sclerosis and Autism spectrum disordersTrends Mol Med2011177887[PubMed][Google Scholar]
103. SahinMTargeted treatment trials for tuberous sclerosis and autism: no longer a dreamCurr Opin Neurobiol2012225895901[PubMed][Google Scholar]
104. de VriesPJTargeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complexNeurotherapeutics20107275282[PubMed][Google Scholar]
105. HampsonDRGholizadehSPaceyLKPathways to drug development for autism spectrum disordersClin Pharmacol Ther201291189200[PubMed][Google Scholar]
106. MiddletonEJrKandaswamiCTheoharidesTCThe effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancerPharmacol Rev200052673751[PubMed][Google Scholar]
107. Van AllerGSCarsonJDTangWPengHZhaoLCopelandRATumminoPJLuoLEpigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitorBiochem Biophys Res Commun2011406194199[PubMed][Google Scholar]
108. KimataMShichijoMMiuraTSerizawaIInagakiNNagaiHEffects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cellsClin Exp Allergy200030501508[PubMed][Google Scholar]
109. AsadiSZhangBWengZAngelidouAKempurajDAlysandratosKDTheoharidesTCLuteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cellsInt J Immunopathol Pharmacol20102310151020[PubMed][Google Scholar]
110. DirscherlKKarlstetterMEbertSKrausDHlawatschJWalczakYMoehleCFuchshoferRLangmannTLuteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotypeJ Neuroinflammation201073[PubMed][Google Scholar]
111. JangSDilgerRNJohnsonRWLuteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged miceJ Nutr201014018921898[PubMed][Google Scholar]
112. KaoTKOuYCLinSYPanHCSongPJRaungSLLaiCYLiaoSLLuHCChenCJLuteolin inhibits cytokine expression in endotoxin/cytokine-stimulated microgliaJ Nutr Biochem201122612624[PubMed][Google Scholar]
113. KempurajDTagenMIliopoulouBPClemonsAVasiadiMBoucherWHouseMWolfergATheoharidesTCLuteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cellsBr J Pharmacol200815510761084[PubMed][Google Scholar]
114. VerbeekRPlompACvan TolEAvan NoortJMThe flavones luteolin and apigenin inhibit in vitro antigen-specific proliferation and interferon-gamma production by murine and human autoimmune T cellsBiochem Pharmacol200468621629[PubMed][Google Scholar]
115. FrancoJLPosserTMissauFPizzolattiMGDos SantosARSouzaDOAschnerMRochaJBDafreALFarinaMStructure-activity relationship of flavonoids derived from medicinal plants in preventing methylmercury-induced mitochondrial dysfunctionEnviron Toxicol Pharmacol201030272278[PubMed][Google Scholar]
116. ChenHQJinZYWangXJXuXMDengLZhaoJWLuteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activationNeurosci Lett2008448175179[PubMed][Google Scholar]
117. JangSWLiuXYepesMShepherdKRMillerGWLiuYWilsonWDXiaoGBlanchiBSunYEYeKA selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavoneProc Natl Acad Sci USA201010726872692[PubMed][Google Scholar]
118. SadakataTShinodaYOkaMSekineYSatoYSarutaCMiwaHTanakaMItoharaSFuruichiTReduced axonal localization of a Caps2 splice variant impairs axonal release of BDNF and causes autistic-like behavior in miceProc Natl Acad Sci USA2012109512110421109[PubMed][Google Scholar]
119. TheoharidesTCAsadiSPanagiotidouSA case series of a luteolin formulation (Neuroprotek®) in children with autism spectrum disordersIntl J Immunopathol Pharmacol201225317323[Google Scholar]